Floatz logo

m3814

Gliosarcoma

M.D. Anderson Cancer CenterPhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

38 Active assets in the Gliosarcoma cohort.

Asset / SponsorPhaseRating
Irinotecan
RTOG Foundation, Inc.
Phase 3BB
(+)-VINCRISTINE
RTOG Foundation, Inc.
Phase 3BB
Cyclophosphamide
Mayo Clinic
Phase 2BB
Nivolumab
Andrew P. Groves
Phase 2/3BB
Ipilimumab
University College, London
Phase 2/3BB

View all 50 →

Same molecule, other indications

m3814 is also rated in:

Advanced Solid TumorsDormant
CCC
Indicative ·
52 / 100
View asset →
Unresectable Malignant Solid NeoplasmDormant
CCC
Indicative ·
50 / 100
View asset →
Locally Advanced Unresectable Gallbladder CarcinomaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →